Multilateral project for analyzing effects of pharmaceutical mergers
The Competition Bureau has joined its counterparts in the United States, the United Kingdom, and the European Union in launching an international working group to develop updated approaches for analyzing the effects of pharmaceutical mergers.
Initiated by the U.S. Federal Trade Commission, the working group also includes the European Commission Directorate-General for Competition, the U.K.’s Competition and Markets Authority, the U.S. Department of Justice, and Offices of State Attorneys General, a press release said.
The joint project brings together a number of the Bureau’s key partners to ensure effective enforcement in a crucial sector of the Canadian and global economy. The goal of the initiative is to identify concrete steps to review and update the analysis of pharmaceutical mergers, which are often subject to review in multiple jurisdictions.
The working group will examine a variety of issues related to mergers in the pharmaceutical industry, including potential updates and expansion of current theories of harm, the evaluation of the full range of effects of a merger on innovation, as well as potential remedies to resolve emerging concerns.